The Role of resistin in inflammatory myopathies

Current Rheumatology Reports

Volumn 15, Issue 6, 2013, Pages

  Filková, Mária ^a   Šenolt, Ladislav ^a   Vencovský, Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Idiopathic inflammatory myopathies; Idiopathic inflammatory myositis; Inflammation; Inflammatory cytokines; Resistin

Indexed keywords

GAMMA INTERFERON; GLUCOCORTICOID; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; CYTOKINE; RETN PROTEIN, HUMAN;

ARTHRITIS; ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; MUSCLE TISSUE; MYOSITIS; NONHUMAN; PATHOGENESIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ANIMAL; BLOOD; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; ENDOTHELIUM CELL; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW; UPREGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; BIOLOGICAL MARKERS; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CHEMOTAXIS; CYTOKINES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; HUMANS; MYOSITIS; RESISTIN; UP-REGULATION;

EID: 84876134063     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-013-0336-0     Document Type: Article

References (71)

1. Lundberg IE, Grundtman C. Developments in the scientific and clinical understanding of inflammatory myopathies. Arthritis Res Ther. 2008;10:220.
2. Li CK, Knopp P, Moncrieffe H, et al. Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositis. Am J Pathol. 2009;175:1030-40.
3. •• Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol. 2010;10:346-52. Systematic review of the literature on the pathogenesis and management of inflammatory muscle diseases.
4. Figarella-Branger D, Civatte M, Bartoli C, et al. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve. 2003;28:659-82. (Pubitemid 37484828)
5. De Paepe B, Creus KK, De Bleecker JL. Role of cytokines and chemokines in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2009;21:610-6.
6. • Nasr R, Reed AM, Peterson EJ. Update: biomarkers for idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2012;24:609-15. Systematic review of new biomarkers for idiopathic inflammatory myopathies.
7. • Gómez R, Conde J, Scotece M, et al. What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol. 2011;7:528-36. Systematic review of the literature on the role of adipokines in rheumatic diseases.
8. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409:307-12. (Pubitemid 32151228)
9. Filková M, Haluzík M, Gay S, et al. The role of resistin as a regulator of inflammation: implications for various human pathologies. Clin Immunol. 2009;133:157-70.
10. Savage DB, Sewter CP, Klenk ES, et al. Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes. 2001;50:2199-202. (Pubitemid 33641901)
11. Lu SC, Shieh WY, Chen CY, et al. Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett. 2002;530:158-62. (Pubitemid 35248204)
12. Anderson PD, Mehta NN, Wolfe ML, et al. Innate immunity modulates adipokines in humans. J Clin Endocrinol Metab. 2007;92:2272-9. (Pubitemid 46997133)
13. Lehrke M, Reilly MP, Millington SC, et al. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 2004;1:e45. (Pubitemid 40412718)
14. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-76. (Pubitemid 37174535)
15. Kaser S, Kaser A, Sandhofer A, et al. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309:286-90. (Pubitemid 37025889)
16. Patel L, Buckels AC, Kinghorn IJ, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300:472-6. (Pubitemid 38375833)
17. Boström EA, Tarkowski A, Bokarewa M. Resistin is stored in neutrophil granules being released upon challenge with inflammatory stimuli. Biochim Biophys Acta. 2009;1793:1894-900.
18. Lee JH, Ort T, Ma K, et al. Resistin is elevated following traumatic joint injury and causes matrix degradation and release of inflammatory cytokines from articular cartilage in vitro. Osteoarthr Cartil. 2009;17:613-20.
19. • Zhang J, Lei T, Chen X, et al. Resistin up-regulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathway. Inflammation. 2010;33:25-33. Potential implication of resistin in inflammatory signaling pathways.
20. Bertolani C, Sancho-Bru P, Failli P, et al. Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells. J Pathol. 2006;169:2042-53. (Pubitemid 351181964)
21. Son YM, Ahn SM, Kim GR, et al. Resistin enhances the expansion of regulatory T cells through modulation of dendritic cells. BMC Immunol. 2010;11:33.
22. Silswal N, Singh AK, Aruna B, et al. Human resistin stimulates the pro-inflammatory cytokines TNF-alpha and IL-12 in macrophages by NFkappaB-dependent pathway. Biochem Biophys Res Commun. 2005;334:1092-101. (Pubitemid 41074686)
23. Bokarewa M, Nagaev I, Dahlberg L, et al. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174:5789-95. (Pubitemid 40593223)
24. •• Tarkowski A, Bjersing J, Shestakov A, et al. Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med. 2010;14:1419-31. The original report demonstrating a receptor of resistin.
25. •• Filková M, Hulejová H, Kuncová K, et al. Resistin in idiopathic inflammatory myopathies. Arthritis Res Ther. 2012;14:R111. First report showing the role of resistin in idiopathic inflammatory myopathies.
26. Kim GT, Cho ML, Park YE, et al. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol. 2010;29:273-9.
27. Mackiewicz Z, Hukkanen M, Povilenaite D, et al. Dual effects of caspase-1, interleukin-1 beta, tumour necrosis factor-alpha and nerve growth factor receptor in inflammatory myopathies. Clin Exp Rheumatol. 2003;21:41-8. (Pubitemid 36267530)
28. • Loell I, Lundberg IE. Can muscle regeneration fail in chronic inflammation: a weakness in inflammatory myopathies? J Intern Med. 2011;269:243-57. Summary of molecular and histopathological mechanisms standing behind muscle weakness in idiopathic inflammatory myopathies.
29. Kirman I, Vainer B, Nielsen OH. Interleukin-15 and ist role in chronic inflammatory diseases. Inflamm Res. 1998;47:285-9. (Pubitemid 28379308)
30. Busquets S, Figueras MT, Meijsing S, et al. Interleukin-15 decreases proteolysis in skeletalmuscle: a direct effect. Int J Mol Med. 2005;16:471-6.
31. Kim M, Oh JK, Sakata S, et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol. 2008;45:270-80.
32. Kang S, Chemaly ER, Hajjar RJ, et al. Resistin promotes cardiac hypertrophy via the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways. J Biol Chem. 2011;286:18465-73.
33. Calabro P, Samudio I, Willerson JT, et al. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004;110:3335-40. (Pubitemid 39557496)
34. Lawlor MA, Alessi DR. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci. 2001;114:2903-10. (Pubitemid 32821530)
35. Cohen G, Ilic D, Raupachova J, Hörl WH. Resistin inhibits essential functions of polymorphonuclear leukocytes. J Immunol. 2008;181:3761-8.
36. Walcher D, Hess K, Berger R, et al. Resistin: a newly identified chemokine for human CD4-positive lymphocytes. Cardiovasc Res. 2010;85:167-74.
37. Jung HS, Park KH, Cho YM, et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res. 2006;69:76-85. (Pubitemid 41814813)
38. Ding Q, Chai H, Mahmood N, et al. Matrix metalloproteinases modulated by protein kinase Cε mediate resistin-induced migration of human coronary artery smooth muscle cells. J Vasc Surg. 2011;53:1044-51.
39. Shyu KG, Lien LM, Wang BW, et al. Resistin contributes to neointimal formation via oxidative stress after vascular injury. Clin Sci (Lond). 2011;120:121-9.
40. Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253:269-85. (Pubitemid 37321735)
41. Mu H, Ohashi R, Yan S, et al. Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res. 2006;70:146-57.
42. Wu WT, Chen CN, Lin CI, et al. Lysophospholipids enhance matrix metalloproteinase-2 expression in human endothelial cells. Endocrinology. 2005;146:3387-400. (Pubitemid 41058111)
43. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation. 2003;108:736-40. (Pubitemid 36999260)
44. Kawanami D, Maemura K, Takeda N, et al. Direct reciprocal effects of resistin and adiponectin on vascular endothelial cells: a new insight into adipocytokine-endothelial cell interactions. Biochem Biophys Res Commun. 2004;314:415-9. (Pubitemid 38084733)
45. Hung HF, Wang BW, Chang H, et al. The molecular regulation of resistin expression in cultured vascular smooth muscle cells under hypoxia. J Hypertens. 2008;26:2349-60.
46. •• Chemaly ER, Hadri L, Zhang S, et al. Long-term in vivo resistin overexpression induces myocardial dysfunction and remodeling in rats. J Mol Cell Cardiol. 2011;51:144-55. The role of resistin in multiple mechanisms of cell behaviour and organ homeostasis.
47. Chen C, Jiang J, Lü JM, et al. Resistin decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Am J Physiol Heart Circ Physiol. 2010;299:H193-201.
48. Park JH, Olsen NJ. Utility of magnetic resonance imaging in the evaluation of patients with inflammatory myopathies. Curr Rheumatol Rep. 2001;3:334-45.
49. Niederwanger A, Kranebitter M, Ciardi C, et al. Resistin impairs basal and insulin-induced glycogen synthesis by different mechanisms. Mol Cell Endocrinol. 2007;263:112-9. (Pubitemid 44828236)
50. Palanivel R, Maida A, Liu Y, et al. Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia. 2006;49:183-90. (Pubitemid 43151630)
51. Jørgensen SB, Honeyman J, Oakhill JS, et al. Oligomeric resistin impairs insulin and AICAR-stimulated glucose uptake in mouse skeletal muscle by inhibiting GLUT4 translocation. Am J Physiol Endocrinol Metab. 2009;297:E57-66.
52. Fan HQ, Gu N, Liu F, et al. Prolonged exposure to resistin inhibits glucose uptake in rat skeletal muscles. Acta Pharmacol Sin. 2007;28:410-6.
53. Moon B, Kwan JJ, Duddy N, et al. Resistin inhibits glucose uptake in L6 cells independently of changes in insulin signaling and GLUT4 translocation. Am J Physiol Endocrinol Metab. 2003;285:E106-15.
54. Schaffler A, Ehling A, Neumann E, et al. Adipocytokines in synovial fluid. JAMA. 2003;290:1709-10.
55. Senolt L, Housa D, Vernerová Z, et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis. 2007;66:458-63. (Pubitemid 46580464)
56. Migita K, Maeda Y, Miyashita T, et al. The serum levels of resistin in rheumatoid arthritis patients. Clin Exp Rheumatol. 2006;24:698-701. (Pubitemid 46138804)
57. Forsblad d'Elia H, Pullerits R, Carlsten H, et al. Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. Rheumatology (Oxford). 2008;47:1082-7. (Pubitemid 351865939)
58. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother. 2008;9:1121-8. (Pubitemid 351721750)
59. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, et al. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2008;26:311-6. (Pubitemid 351659139)
60. Klaasen R, Herenius MM, Wijbrandts CA, et al. Treatment-specific changes in circulating adipocytokines: a comparison between tumour necrosis factor blockade and glucocorticoid treatment for rheumatoid arthritis. Ann Rheum Dis. 2012;71:1510-6.
61. Almehed K, d'Elia HF, Bokarewa M, et al. Role of resistin as a marker of inflammation in systemic lupus erythematosus. Arthritis Res Ther. 2008;10:R15. (Pubitemid 351280042)
62. Boström EA, d'Elia HF, Dahlgren U, et al. Salivary resistin reflects local inflammation in Sjögren's syndrome. J Rheumatol. 2008;35(10):2005-11.
63. Johnston A, Arnadottir S, Gudjonsson JE, et al. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159:342-50. (Pubitemid 352009847)
64. Corbetta S, Angioni R, Cattaneo A, et al. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol. 2006;154:83-6. (Pubitemid 43250740)
65. Kocabas H, Kocabas V, Buyukbas S, et al. The serum levels of resistin in ankylosing spondylitis patients: a pilot study. Rheumatol Int. 2012;32:699-702.
66. Hulejová H, Levitová A, Kuklová M, et al. No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis. Clin Rheumatol. 2012;31:67-71.
67. Pehlivan Y, Onat AM, Ceylan N, et al. Serum leptin, resistin and TNF-α levels in patients with systemic sclerosis: the role of adipokines in scleroderma. Int J Rheum Dis. 2012;15:374-9.
68. Gheita TA, El-Gazzar II, El Shazly RI, et al. Elevated serum resistin in juvenile idiopathicarthritis: relation to categories and disease activity. J Clin Immunol. 2012 Aug 11. [Epub ahead of print].
69. • Boström EA, Ekstedt M, Kechagias S, et al. Resistin is associated with breach of tolerance and anti-nuclear antibodies in patients with hepatobiliary inflammation. Scand J Immunol. 2011;74:463-70. Association between resistin and autoantibodies in inflammatory diseases.
70. Isenberg DA, Allen E, Farewell V, et al. International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford). 2004;43(1):49-54. (Pubitemid 38088368)
71. Lundberg IE. New possibilities to achieve increased understanding of disease mechanisms in idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2002;14:639-42. (Pubitemid 35191548)